Free Trial

Gossamer Bio (GOSS) Competitors

-0.01 (-1.95%)
(As of 03:16 PM ET)


Should you be buying Gossamer Bio stock or one of its competitors? The main competitors of Gossamer Bio include Syros Pharmaceuticals (SYRS), Context Therapeutics (CNTX), Sagimet Biosciences (SGMT), InterCure (INCR), Cybin (CYBN), CytomX Therapeutics (CTMX), Repare Therapeutics (RPTX), RAPT Therapeutics (RAPT), Rigel Pharmaceuticals (RIGL), and I-Mab (IMAB). These companies are all part of the "pharmaceutical preparations" industry.

Gossamer Bio vs.

Gossamer Bio (NASDAQ:GOSS) and Syros Pharmaceuticals (NASDAQ:SYRS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, community ranking, earnings, valuation, media sentiment, profitability, analyst recommendations and dividends.

Gossamer Bio currently has a consensus price target of $7.65, suggesting a potential upside of 1,133.87%. Syros Pharmaceuticals has a consensus price target of $14.00, suggesting a potential upside of 170.79%. Given Gossamer Bio's higher probable upside, equities analysts plainly believe Gossamer Bio is more favorable than Syros Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Gossamer Bio
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
Syros Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)

Gossamer Bio has a net margin of 0.00% compared to Syros Pharmaceuticals' net margin of -1,656.34%. Syros Pharmaceuticals' return on equity of -395.36% beat Gossamer Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Gossamer BioN/A -525.73% -62.70%
Syros Pharmaceuticals -1,656.34%-395.36%-88.41%

Syros Pharmaceuticals received 216 more outperform votes than Gossamer Bio when rated by MarketBeat users. However, 65.32% of users gave Gossamer Bio an outperform vote while only 63.89% of users gave Syros Pharmaceuticals an outperform vote.

Gossamer BioOutperform Votes
Underperform Votes
Syros PharmaceuticalsOutperform Votes
Underperform Votes

Syros Pharmaceuticals has higher revenue and earnings than Gossamer Bio. Syros Pharmaceuticals is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gossamer BioN/AN/A-$179.82M-$1.06-0.58
Syros Pharmaceuticals$9.94M13.71-$164.57M-$5.01-1.02

81.2% of Gossamer Bio shares are held by institutional investors. Comparatively, 91.5% of Syros Pharmaceuticals shares are held by institutional investors. 5.0% of Gossamer Bio shares are held by insiders. Comparatively, 12.3% of Syros Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Gossamer Bio has a beta of 1.84, suggesting that its stock price is 84% more volatile than the S&P 500. Comparatively, Syros Pharmaceuticals has a beta of 1.75, suggesting that its stock price is 75% more volatile than the S&P 500.

In the previous week, Syros Pharmaceuticals had 3 more articles in the media than Gossamer Bio. MarketBeat recorded 7 mentions for Syros Pharmaceuticals and 4 mentions for Gossamer Bio. Syros Pharmaceuticals' average media sentiment score of 0.57 beat Gossamer Bio's score of 0.35 indicating that Syros Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Gossamer Bio
0 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Syros Pharmaceuticals
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)


Syros Pharmaceuticals beats Gossamer Bio on 9 of the 17 factors compared between the two stocks.

Get Gossamer Bio News Delivered to You Automatically

Sign up to receive the latest news and ratings for GOSS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GOSS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GOSS vs. The Competition

MetricGossamer BioPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$139.13M$6.73B$5.00B$8.05B
Dividend YieldN/A2.73%2.81%3.93%
P/E Ratio-0.5811.55133.4015.40
Price / SalesN/A258.712,452.2675.54
Price / CashN/A35.7135.9531.61
Price / Book5.135.925.434.60
Net Income-$179.82M$139.39M$104.34M$213.88M
7 Day Performance-11.38%-2.25%-1.47%-1.28%
1 Month Performance-13.17%1.56%2.64%2.96%
1 Year Performance-53.76%-6.51%3.36%7.62%

Gossamer Bio Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
Syros Pharmaceuticals
4.358 of 5 stars
Context Therapeutics
2.7459 of 5 stars
+179.4%$152.25MN/A-1.535Gap Down
Sagimet Biosciences
3.6372 of 5 stars
N/A$152.85M$2M0.008Analyst Forecast
0 of 5 stars
N/A+40.8%$154.04M$355.55M25.39370Upcoming Earnings
1.6976 of 5 stars
N/A$145.81MN/A-1.69N/AGap Down
CytomX Therapeutics
4.7472 of 5 stars
Repare Therapeutics
2.5431 of 5 stars
-71.1%$144.30M$51.13M-3.09179High Trading Volume
RAPT Therapeutics
4.1036 of 5 stars
Rigel Pharmaceuticals
1.2834 of 5 stars
-36.4%$160.33M$116.88M-7.62147Negative News
High Trading Volume
2.617 of 5 stars
-45.3%$142.35M$3.89M0.00228News Coverage

Related Companies and Tools

This page (NASDAQ:GOSS) was last updated on 5/24/2024 by Staff

From Our Partners